Evidence map›Paper›PMID 42092832›Full record

ArticleBMC nephrology2026

Early mortality in multiple myeloma patients with renal impairment: a nested case-control study.

Yan Li, Wenjiao Tang, Bing Xiang, Ling Pan, Yuhuan Zheng, Ting Niu, Li Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan LiDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, No. 37# GuoXue Xiang Street, Chengdu, ZIP 610041, China.
Wenjiao TangDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, No. 37# GuoXue Xiang Street, Chengdu, ZIP 610041, China.
Bing XiangDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, No. 37# GuoXue Xiang Street, Chengdu, ZIP 610041, China.
Ling PanDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, No. 37# GuoXue Xiang Street, Chengdu, ZIP 610041, China.
Yuhuan ZhengDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, No. 37# GuoXue Xiang Street, Chengdu, ZIP 610041, China.
Ting NiuDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, No. 37# GuoXue Xiang Street, Chengdu, ZIP 610041, China.
Li ZhangDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, No. 37# GuoXue Xiang Street, Chengdu, ZIP 610041, China. drzhangli2014@sina.com.

Funding

Key Research Project of Sichuan Anti-Cancer Association Clinical Research XH2023 5008Sichuan Medical Science & Technology Innovation Research Association YCH-KY-YCZD2024-106
6 · The paper itself

Abstract

backgroundRenal impairment (RI) in multiple myeloma (MM) patients significantly impacts outcomes, yet the prevalence and causes of early mortality within 12 months of diagnosis in newly diagnosed MM (NDMM) with RI are understudied in the novel agent era.

methodsThis study conducted a nested case-control analysis including 199 NDMM patients with RI from West China Hospital from June 2016 to November 2022. Among this cohort, we identified 19 cases of early mortality (death within 12 months of diagnosis) and selected 76 matched controls from the remaining patients at a 1:4 ratio based on age, gender, and diagnosis date. All controls were followed for over one year. Potential risk factors including elevated N-terminal pro-brain natriuretic peptide (NT-proBNP), heart failure at diagnosis, and other clinical indicators were analyzed.

resultsThe incidence of early death was determined to be 9.5% (19/199) in MM with RI, with pneumonia as the leading cause. Compared to controls, the case group exhibited a higher prevalence of elevated lactate dehydrogenase (LDH) levels and pneumonia. Multivariable logistic regression identified elevated LDH levels and pneumonia at diagnosis as independent risk factors for early mortality, whereas NT-proBNP elevation and heart failure at onset did not show statistically significant associations. The 1-year overall survival rates for MM with RI were 95.3% with 0 risk factors, 85.2% with 1 risk factor, and 68.8% with 2 risk factors (p < 0.001).

conclusionsIn this nested case-control study of NDMM patients with RI, elevated LDH levels and pneumonia at diagnosis were identified as independent risk factors for early mortality in NDMM patients with renal impairment.

Indexed as

Multiple MyelomaRenal InsufficiencyAgedCase-Control StudiesChinaFemaleHumansL-Lactate DehydrogenaseMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPneumoniaRisk FactorsL-Lactate DehydrogenaseNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Early mortalityMultiple myelomaNested case-controlRenal impairment

Identifiers

PMID42092832
PMCPMC13317205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.